

### **AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1.-25. (cancelled)

26. (currently amended)      A device for delivering a medicament to a patient, comprising  
an output port defining a passage for dispensing controlled release particles of a  
cohesive composite of a medicament and a pharmaceutically acceptable carrier to a patient;  
a chamber containing the cohesive composite particles of the medicament and the  
pharmaceutically acceptable carrier, the pharmaceutically acceptable carrier comprising xanthan  
gum and locust bean gum, wherein the average particle size of said cohesive composite particles  
is from about 0.1 to about 125 microns in diameter; and  
an actuator coupled to the chamber, the actuator selectively causing the cohesive  
composite particles to be dispensed to the patient through the passage of the output port.

27. (previously presented)      The device of claim 26, wherein said pharmaceutically acceptable  
carrier comprises said xanthan gum and said locust bean gum in a ratio of from about 1:3 to  
about 3:1.

28. (previously presented)      The device of claim 26, wherein the average particle size of said  
cohesive composite particle is from about 0.1 to about 10 microns.

29. (previously presented)      The device of claim 26, wherein the average particle size of said  
cohesive composite particle is from about 10 to about 125 microns.

30. (previously presented)      The device of claim 26, wherein the medicament to gum ratio is  
from about 0.5:100 to about 1:1.

31. (previously presented)      The device of claim 30, wherein the medicament to gum ratio is  
from about 1:100 to about 1:2.

32. (previously presented) The device of claim 26, further comprising from about 0.1 to about 50% by weight of a cationic cross-linking agent comprising an alkaline metal or an alkaline earth metal sulfate, chloride, borate, bromide, citrate, acetate or lactate.

33. (previously presented) The device of claim 32, wherein said cationic cross-linking agent is present in an amount of from about 1 to about 10% by weight.

34. (previously presented) The device of claim 32, wherein said cationic cross-linking agent is selected from the group consisting of potassium chloride and sodium chloride.

35. (previously presented) The device of claim 26, wherein said pharmaceutically acceptable carrier further comprises an inert saccharide diluent selected from the group consisting of monosaccharides, disaccharides and mixtures thereof.

36. (previously presented) The device of claim 35, wherein said inert saccharide diluent is selected from the group consisting of dextrose, sucrose, galactose, lactose and mixtures thereof.

37. (previously presented) The device of claim 26, wherein said pharmaceutically acceptable carrier further comprises a pharmaceutically-acceptable surfactant in an amount of from about 0.5 to about 3% by weight of the controlled release carrier.

38. (previously presented) The device of claim 37, wherein said surfactant is selected from the group consisting of pharmaceutically-acceptable anionic surfactants, cationic surfactants, amphoteric (amphipathic/amphophilic) surfactants, non-ionic surfactants, and mixtures thereof.

39. (previously presented) The device of claim 26, wherein said controlled release particles are compressed together to form a solid mass.

40. (previously presented) The device of claim 26, wherein said controlled release pharmaceutical is suitable for delivery to the upper respiratory tract of a human patient.

41. (previously presented) The device of claim 26, wherein said controlled release pharmaceutical is suitable for oral insufflation therapy.
42. (previously presented) The device of claim 26, wherein said cohesive composite is in the form of a granulate.
43. (currently amended) A device for delivering a medicament to a patient, comprising a cohesive composite of a medicament together with a pharmaceutically acceptable carrier comprising xanthan gum and locust bean gum, wherein the average particle size of said cohesive composite particles is from about 0.1 to about 125 microns in diameter; and means for delivering the cohesive composite to a nasal or oral ~~orifice~~ orifice.